Evolution of myeloid-mediated immunotherapy resistance in prostate cancerAram Lyu, Lawrence Fong, Zenghua Fan et al.|Nature|2024Cited by 138
Sequential JAK inhibition enhances antitumor immunity after combined anti–PD-1 and anti-CTLA4Marcel Arias-Badia, Lawrence Fong, Peixi Chen et al.|JCI Insight|2025Cited by 4
674 Multi-omic single-cell assessment of castration-resistant prostate cancer patients receiving ¹ <sup>7</sup> <sup>7</sup> Lu-PSMA-617 and pembrolizumab shows timing of radioligand therapy alters immune responseAnusha Muralidhar, Lawrence Fong, Karen Law et al.|Regular and Young Investigator Award Abstracts|2025Cited by 0
463 Dissecting myeloid-driven mechanisms of immunotherapy resistance in prostate cancer bone metastasesAram Lyu, Lawrence Fong, Zenghua Fan et al.|Regular and Young Investigator Award Abstracts|2025Cited by 0
Abstract 4084: Dissecting myeloid-driven mechanisms of immunotherapy resistance in prostate cancer bone metastasesAram Lyu, Lawrence Fong, Zenghua Fan et al.|Cancer Research|2026Cited by 0